Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

Gremlin 2, human recombinant

Inhibitor of BMP-2, -4, and -7
Catalog #: 4657
SKU-Size Size Price Qty
4657-20 20 μg
4657-100 100 μg
4657-1000 1 mg
More Sizes Get Quote

Product Details

Alternate Name Gremlin-2, Cysteine knot superfamily 1, BMP antagonist 2, Protein related to DAN and cerberus, DAN domain family member 3
Gene Symbol GREM2
Gene ID 64388
Accession # Q9H772
Source E. coli
Appearance Lyophilized protein
Physical Form Description Sterile filtered and lyophilized with no additives
Molecular Weight 17.2 kDa
Purity by SDS-PAGE ≥95%
Purity by ≥95%
Endotoxin Level <0.1 ng/μg
Biological Activity Test in process
Reconstitution Instructions Reconstitute to 1 mg/ml with sterilized dH₂O. Pipette to dissolve the protein pellet completely
Handling Centrifuge the vial prior to opening.
Storage Conditions -20°C
USAGE For Research Use Only! Not to be used in humans


Gremlin (also known as Increased in High Glucose Protein 2, IHG-2, Down-regulated in Mos-transformed cells protein, Drm) functions as a bone morphogenetic protein (BMP) antagonist. It acts by binding to, and forming heterodimers with BMP-2, BMP-4, BMP-7, thus preventing them from interacting with their cell surface receptors. Recombinant human Gremlin-2 is a N-terminus His-tagged protein that was expressed from E. coli.

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.